A two week treatment, multi-center, randomized, openlabel, assessor blinded, parallel group study of QAE397 400 g, o.d. QAE397 1200 g o.d. , budesonide 100 g, o.d. , or budesonide 400 g, b.i.d. delivered via SDDPI in moderate to severe asthmatic patients

Trial Profile

A two week treatment, multi-center, randomized, openlabel, assessor blinded, parallel group study of QAE397 400 g, o.d. QAE397 1200 g o.d. , budesonide 100 g, o.d. , or budesonide 400 g, b.i.d. delivered via SDDPI in moderate to severe asthmatic patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2011

At a glance

  • Drugs Budesonide; QAE 397
  • Indications Asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top